These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35843628)

  • 41. Epithelioid inflammatory myofibroblastic sarcoma with recurrence after extensive resection: significant clinicopathologic characteristics of a rare aggressive soft tissue neoplasm.
    Zhou J; Jiang G; Zhang D; Zhang L; Xu J; Li S; Li W; Ma Y; Zhao A; Zhao Z
    Int J Clin Exp Pathol; 2015; 8(5):5803-7. PubMed ID: 26191301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.
    Kopelevich A; Holzman SA; La J; Lai HA; Torno L; Stephany HA
    Urology; 2021 Mar; 149():222-224. PubMed ID: 32882306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
    Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
    Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report.
    Chennouf A; Arslanian E; Roberge D; Berthelet F; Bojanowski M; Bahary JP; Masucci L; Belanger K; Florescu M; Wong P
    Cureus; 2017 Mar; 9(3):e1068. PubMed ID: 28409069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
    Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
    Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epithelioid Inflammatory Myofibroblastic Sarcoma of the Ovary With RANB2-ALK Fusion: Report of a Case.
    Fang H; Langstraat CL; Visscher DW; Folpe AL; Schoolmeester JK
    Int J Gynecol Pathol; 2018 Sep; 37(5):468-472. PubMed ID: 28787324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epithelioid Fibrous Histiocytoma with
    Secco LP; Libbrecht L; Seijnhaeve E; Eggers S; Dekairelle AF; De Roo AK
    Dermatopathology (Basel); 2023 Jan; 10(1):25-29. PubMed ID: 36648781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory Myofibroblastic Tumor of the Esophagus and Stomach Successfully Treated With ALK Inhibitor in a Pediatric Patient: A Case Report and Concise Review of Literature.
    Billingsley BC; Chaudhary R; Morris MW; Cox JA; Camacho-Gomez SM; Varshney N
    Int J Surg Pathol; 2024 Apr; ():10668969241246470. PubMed ID: 38656257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
    Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
    Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity.
    Kozu Y; Isaka M; Ohde Y; Takeuchi K; Nakajima T
    Gen Thorac Cardiovasc Surg; 2014 Mar; 62(3):191-4. PubMed ID: 23345154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
    Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
    J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
    Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
    Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
    Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
    J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
    Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
    Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
    Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
    Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
    Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
    Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.